Eclipse Diagnostics offering is now closed and is no longer accepting investments.

INVEST IN ECLIPSE DIAGNOSTICS TODAY!

Grower-friendly cannabis test

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Eclipse Diagnostics

$179,058.00 Raised

REASONS TO INVEST

ABOUT

HEADQUARTERS

750 N San Vicente Blvd
Los Angeles, CA 90069
VALUATION

$11.19M

TEAM

Luka Fajs
Luka Fajs
President, CEO, Director

Luka comes from Slovenia and holds a PhD in Medical Microbiology from the University of Ljubljana, Slovenia. Before starting the Company, he was doing research and clinical laboratory diagnostics of hemorrhagic fevers, biothreats and other infectious diseases. He spent a lot of time in the field, helping doctors and nurses in low-income countries to set up and improve their diagnostic preparedness. During his work, he saw first-hand the drawbacks of the existing medical diagnostics system that is mostly centralized, capital-intensive and many people do not have adequate access to it. That was the motivation to join Prof. Robert’s laboratory in Singapore where he took over the fundraising and startup activities of the technology. He continued as CEO of Biosensorix and helped secure early funding and directed the research and development activities. He is a passionate entrepreneur with a deep knowledge of diagnostics, user expectations, and basic science. Jan 2014 - Dec 2014: Post-doc at Institute of Microbiology and Immunology, University of Ljubljana, Slovenia - research and clinical diagnostics of viral hemorrhagic fevers and other zoonoses Jan 2015 - Dec 2016: Post-doc at Nanyang Technological University, Singapore - research and development of diagnostic and environmental monitoring platforms Nov 2015 - present: cofounder, CEO and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder, president, CEO and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Prof. Robert S. Marks
Prof. Robert S. Marks
Chief Scientist, Director

Prof. Dr. Robert S. Marks is the co-inventor of the technological platform and is a renowned expert and key opinion leader in the field of biosensors. He is a Full Professor at the Ben-Gurion University of the Negev, Israel, at the Department of Biotechnology Engineering, The National Institute for Biotechnology in the Negev and the Ilse Kats Centre for Nanotechnology. He was a Visiting Scientist in the NTU-MSE, and was a program coordinator for the NRF CREATE program "Nanomaterials for Water and Energy Management". Robert has previously co-founded Biosensing Technologies Ltd, Biopixel Ltd and Polyrizon Ltd. He will be assisting with advising the development of the next generation prototype and establishing the business collaboration with potential partners. Prof. Marks has extensive experience in development of biosensors. He is the Editor-in-Chief of a 2007 2-volume Wiley Handbook in Biosensors and Biochips and a 2014 Viral Diagnostics book for virus detection. He is the author of 150+ papers (H-index 27), and numerous chapters. He has 4 issued patents as well as a dozen filed. 2011-present: Full Professor at Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel Jan 2012 - Dec 2016: Visiting Professor at Nanyang Technological University, Singapore July 2011 - Jun 2016: Coordinator at NRF (National Research Foundation) CREATE Center for Nanomaterials for Energy and Water Management, Singapore Nov 2015 - present: cofounder and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Tina Semolic

Tina Semolic

Marketing Advisor

Marketing advisor at Biosensorix Pte. Ltd. Previously at Adglow.com (clients: Prada, Miu Miu, Moschino, Pinko, Max Mara, Armani ect.), Httpool.com (over 50 clients: Generali insurance, Mercedes, Audi, STO - Slovenian touristic org. ect.), Adroll.com (Head of Business Development SMB) Facebook.com (over 500 clients: Adidas, Nike, Ferrari, illy, Morellato, Fossil, Head, Hugs ect.)

TERMS

Eclipse Diagnostics
Overview
PRICE PER SHARE
$11
DEADLINE
Apr 30, 2020
VALUATION
$11.19M
AMOUNT RAISED
$179,058.00
Breakdown
MIN INVESTMENT
$495.00
MAX INVESTMENT
$109,989.00
MIN NUMBER OF SHARES OFFERED
909
OFFERING TYPE
Equity
ASSET TYPE
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
33,020

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Eclipse Diagnostics Inc.

Corporate Address

:

750 N. San Vicente Blvd, Los Angeles, CA 90069

Offering Minimum

:

$9,999.00

Offering Maximum

:

$363,220.00

Minimum Investment Amount

(per investor)

:

$495.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

909

Maximum Number of Shares Offered*

:

33,020

Price per Share

:

$11.00

Pre-Money Valuation

:

$11,189,805.00










*Maximum subject to adjustment for bonus shares. See 10% Bonus below


Perks*

All investors

Regular updates on our technology progress


$5,000+

Exclusive content and regular company updates 

Your place on the Technology Ambassadors Page of the website

1 Canabinox test kit


$10,000+

Exclusive content and regular company updates 

Your place on the Technology Ambassadors Page of the website

2 Canabinox test kits

Invitation to our annual company VIP events 


$50,000+

Exclusive content and regular company updates 

Your place on the Technology Ambassadors Page of the website

4 Canabinox test kits

Once-a-year conference call with the CEO and founders


*All perks occur only after the offering is completed and if the products are available in the market


The 10% Bonus for StartEngine Shareholders

Eclipse Diagnostics Inc. will offer 10% additional bonus shares for all investments that are committed, within 24 hours of this offering going live, by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 in the StartEngine Reg A offering which closed earlier this year.

StartEngine shareholders who invested $1,000 or more in that StartEngine Reg A offering will receive a 10% bonus on this offering within a 24-hour window of this offering’s launch date. This means you will receive a bonus for any shares you purchase. For example, if you buy 10 shares of Common Stock at $11 / share, you will receive 11 Common Stock shares, meaning you'll own 11 shares for $110. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors received their countersigned StartEngine Crowdfunding Inc. subscription agreement.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Any expense labeled “Administrative Expenses” not strictly for administrative purposes; Any expense labeled “Travel and Entertainment”; Inter company debt or back payments; Salary payments made to one’s self, a friend or relative; Vendor payments

ALL UPDATES

05.01.20

Notice to Investors

We will be unable to meet our April 29, 2020, annual report filing requirements for securities sold pursuant to Regulation CF as a result of administrative delays caused by shutdowns due to the COVID pandemic. As such, we intend to rely on the temporary relief being provided by the Securities and Exchange Commission. We will continue to use our best efforts to comply with our ongoing reporting obligations.


Thank you for your continued support. 


Eclipse Diagnostics Team

04.28.20

Campaign Ending Soon. Last chance to invest.

Dear Investors,


Our campaign is ending tomorrow, April 29, 2020 at 11:59pm, so this is your last chance to invest in our Company and be part of our mission to provide easy, rapid and accurate testing for for medical and non-medical applications. We would like to thank all our investors so far and hope to be back soon.

Eclipse Diagnostics team

04.06.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

03.19.20

Eclipse Diagnostics March Update

Dear Investors,


We have some great updates on our research and development progress!


Laboratory Validations

We have been busy optimizing the performance and improving the design of our Eclipse THC/CBD reader. In the past months, we have continued to optimize both our hardware as well as software algorithms to enable a wider range of detection capabilities. We have made great progress in increasing the accuracy of our device from the initial 12% variability to the current 2% variability (THC(A)) measurements! We have performed our testing primarily on samples that had THCA levels between 3% and 30% and very low CBD levels, therefore we are now expanding our validation efforts to include all relevant THC(A) and CBD(A) combinations. 

One of the key lessons learned during this process was that there is a large variability between laboratory data (that we rely on for the calibration) from different labs - inter-lab variability. The inter-lab variability can even range up to 50%! Therefore our main efforts were focused on identifying and partnering with reputable and reliable laboratories in the U.S. We anticipate that we will start our final round of laboratory validations in the coming weeks. This is, of course, dependent on the restrictions in place due to the Covid-19 outbreak.


A specific effort will be to validate the device for the differentiation of hemp vs. non-hemp to enable growers peace of mind during cultivation (crops that go above the legal cut-off of 0.3% THC get destroyed) and to provide law enforcement a tool to rapidly differentiate the same and prevent unnecessary shipment delays and damage to products.


Updated reader design

We have also been working on finalizing the design of the reader for mass production. This means that we had to redesign the case from a 3D-printable design to a design suitable for injection molding. We have completed this and improved the usability of the device by adding a hinge that now holds the reader cap in place and enables a more care-free operation. We have also identified suitable subcontractors for the manufacturing of the molds, as well as other components of the reader.

Updated branding 

We designed a new logo and would like to hear your opinion! The goal of Eclipse Diagnostics is to provide a wide range of diagnostic products, from medical and non-medical applications and we want our branding to reflect that. We are also redesigning the website that will be available soon (we'll let you know when it's live).



Government grants

We submitted a DoD SBIR grant proposal with regard to the call topic "Diagnostic Platform for Rapid Identification of Pathogens in Infected Wounds that is Useable in a Battlefield Environment". We will be submitting more applications for government funding in the coming months, based on the applicability of the grant calls.


What's left to do

  • The key activity is the final laboratory validation of the Eclipse reader system. With more data, we will be able to provide final performance specifications and test a wide range of samples.
  • Finalize packaging design 
  • Injection molding of the case units
  • Final assembly of the readers

We have received great interest from customers in the US, Europe, and Asia and believe that we can start fulfilling orders within weeks of completing the above tasks.


Impact of Covid-19

In light of the ongoing outbreak of Covid-19, we continue our research and development, we are enforcing social distancing and promote work from home as much as possible. The components of the Eclipse reader are readily available and we have not seen a significant impact on our supply chain. We anticipate that the Covid-19 will increase the demand for home/field testing solutions as access to laboratory testing could be limited.


Eclipse Diagnostics

03.17.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

03.09.20

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

02.03.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

01.16.20

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

01.07.20

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:


Extended length of campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

12.19.19

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$179,058.00
INVESTORS
151
MIN INVEST
$495.00
VALUATION
$11.19M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.